NewAmsterdam Pharma Company N.V. (NAMS) Stock Forecast
NAMS analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.69 / 5 from 16 analysts
- Price target
- $49.93 average of analyst targets
- Upside to target
- +151.8% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.50
- 52-week range
- $19.83 – $41.45
NAMS analyst ratings
16 analystsNumber of analysts at each rating.
NAMS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NAMS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.44 | −$0.54 | −$0.29 | −$0.53 | +18.0% | 13 |
| Current fiscal year (2026) | −$1.66 | −$1.87 | −$1.43 | −$1.45 | −14.1% | 12 |
| Next fiscal year (2027) | −$1.55 | −$2.74 | $1.88 | −$1.64 | +5.5% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NAMS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.4M | $0 | $21.8M | +2,013.8% | 15 |
| Current fiscal year (2026) | $24.8M | $5.8M | $40.5M | +30.1% | 16 |
| Next fiscal year (2027) | $119.9M | $8.7M | $524.4M | +384.1% | 15 |
NAMS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NAMS revenue: reported and forecast
NAMS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$0.45 | −$0.45 | −$0.43 | −$0.44 | +3.5% | 1 up · 5 down |
| Current fiscal year (2026) | −$1.59 | −$1.66 | −$1.66 | −$1.65 | −$1.66 | +4.4% | 2 up · 4 down |
| Next fiscal year (2027) | −$1.32 | −$1.38 | −$1.53 | −$1.55 | −$1.55 | +17.4% | 2 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NAMS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NAMS beat in 8 of 12.
What analysts expect from NAMS
16 analysts cover NewAmsterdam Pharma; their consensus rating is strong buy (4.69 on a 1–5 scale, where 5 is a strong buy). The average price target is $49.93, 151.8% above the latest close of $19.83. Analysts expect earnings of −$1.66 per share for 2026, −14.1% from a year earlier. For 2027 the average estimate is −$1.55 per share on revenue of $119.9 million. NewAmsterdam Pharma beat the EPS estimate in 8 of the last 12 quarters.
Related: NAMS income statement, NAMS key metrics, NAMS chart. See the NAMS stock overview for the latest quote and news.
NAMS forecast FAQ
What is NewAmsterdam Pharma's price target?
The average analyst price target for NewAmsterdam Pharma is $49.93, 151.8% above the latest close of $19.83.
Is NewAmsterdam Pharma a buy, hold or sell?
Of 16 analysts covering NewAmsterdam Pharma, 12 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NewAmsterdam Pharma's EPS forecast?
Analysts forecast −$1.66 per share for 2026 (range −$1.87 to −$1.43); for 2027 the estimate is −$1.55.
What is NewAmsterdam Pharma's revenue forecast?
The average revenue estimate for 2026 is $24.8 million, growth of 30.1%; for 2027 it is $119.9 million.
When does NewAmsterdam Pharma report earnings?
NewAmsterdam Pharma is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $-0.50.
Does NewAmsterdam Pharma usually beat earnings estimates?
NewAmsterdam Pharma reported EPS at or above the analyst estimate in 8 of the last 12 quarters.